(Q47770763)

5 February 2018

title

In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice (English)

1 reference

5 February 2018

4

Clemens Löwik

1 reference

5 February 2018

Ivo Que

2

object named as

Ivo Que

1 reference

5 February 2018

Wim Jiskoot

5

object named as

Wim Jiskoot

1 reference

5 February 2018

author name string

Vasco Filipe

1

1 reference

5 February 2018

John F Carpenter

3

1 reference

5 February 2018

publication date

15 August 2013

1 reference

5 February 2018

published in

Pharmaceutical Research

1 reference

5 February 2018

volume

31

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

216-227

1 reference

5 February 2018

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Effects of protein aggregates: an immunologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Lymphatic transport of proteins after subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Early development of therapeutic biologics--pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Neonatal Fc receptor and IgG-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

In vivo optical imaging and dynamic contrast methods for biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

A critical review of methods for size characterization of non-particulate protein aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Development trends for human monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Structural characterization of a human Fc fragment engineered for extended serum half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Structure-immunogenicity relationships of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1154-9

Subvisible Particle Counting Provides a Sensitive Method of Detecting and Quantifying Aggregation of Monoclonal Antibody Caused by Freeze-Thawing: Insights Into the Roles of Particles in the Protein Aggregation Pathway

21 January 2018

1 reference

12 December 2020

Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice

1 reference

12 December 2020

Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology

1 reference

12 December 2020

Pipelines turn to biotech

1 reference

12 December 2020

Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles.

1 reference

12 December 2020

Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice

1 reference

12 December 2020

Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells

1 reference

12 December 2020

Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs

1 reference

12 December 2020

Mechanisms of subcutaneous absorption of rituximab in rats

1 reference

12 December 2020

The role of soluble aggregates in the primary immune response of mice to human gamma globulin

1 reference

12 December 2020

The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model

1 reference

12 December 2020

Some Points of the Mechanism of Filtration by the Spleen.

1 reference

12 December 2020

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats

1 reference

12 December 2020

10.1007/S11095-013-1154-9

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018